Launched in late 2015, sales of Nucala have been mounting and last quarter it generated sales of around £91 million. GSK has also filed Nucala with the FDA as a treatment for COPD. Analyst ...
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
Hosted on MSN4mon
GSK's Respiratory Drug Nucala Meets Goal in COPD StudyGSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.
Hosted on MSN1mon
FDA to review GSK’s Nucala for COPDThe US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary ...
all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab ...
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback